文献速递鼻科小儿耳鼻咽喉

尘螨皮下免疫治疗对单一致敏和多致敏过敏性鼻炎患儿的长期疗效与安全性

Long-Term Efficacy and Safety of Subcutaneous Immunotherapy in Monosensitized and Polysensitized Children With Allergic Rhinitis.
PubMed 文献 · Otolaryngol Head Neck Surg · 2023-12-17

前瞻性队列研究纳入130例尘螨过敏性鼻炎患儿,分为单一致敏组和多致敏组,均接受3年尘螨皮下免疫治疗并随访5年。两组疗效与安全性相似,单一致敏组在停止治疗2年后获益更多。

要点

  • 两组在治疗3年时疗效无显著差异(P > .05)。
  • 两组症状评分和用药评分在治疗1、2、3年及停药2年均较基线显著降低(P < .05)。
  • 两组间评分在治疗期间无显著差异,停药2年时单一致敏组更优(P < .05)。

核心结论

  • 单一致敏和多致敏患儿接受3年尘螨皮下免疫治疗后疗效和安全性相似。
  • 单一致敏患儿在停止治疗2年后获益更多。

研究设计与样本

  • 前瞻性队列研究,纳入130例尘螨过敏性鼻炎患儿。
  • 分为单一致敏组(仅尘螨致敏)和多致敏组(除尘螨外至少1种其他过敏原致敏)。
  • 所有患儿接受针对尘螨的皮下免疫治疗3年,随后监测5年。

主要发现

  • 51例单一致敏和50例多致敏患儿完成研究。
  • 治疗3年时,47例单一致敏和46例多致敏患儿治疗有效,组间疗效无显著差异(P > .05)。
  • 两组鼻部症状总分、症状与用药评分、视觉模拟评分和鼻结膜炎生活质量问卷评分在治疗1、2、3年及停药2年均较基线显著降低(P < .05)。
  • 两组间上述评分在基线、治疗1、2、3年时无显著差异(P > .05),但在停药2年时差异显著(P < .05)。
  • 未报告严重不良事件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy and safety of dust mite subcutaneous immunotherapy (SCIT) in monosensitized and polysensitized children with allergic rhinitis (AR). STUDY DESIGN: Prospective cohort study. SETTING: Tertiary referral center. METHODS: One hundred thirty children were enrolled and categorized into 2 groups: monosensitized to only dust mites and polysensitized to at least 1 additional allergen beyond dust mites. All patients received SCIT targeting dust mites for 3 years, followed by a 5-year monitoring period. The Total Nasal Symptom Score (TNSS), Symptom and Medication Score (SMS), Visual Analogue Scale (VAS), and Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) were assessed before SCIT (T0); at 1 (T1) and 2 (T2) years of SCIT; immediately after SCIT (T3); and 2 years post-SCIT (T5). Safety was assessed based on adverse events (AEs). RESULTS: Fifty-one monosensitized and 50 polysensitized children completed the study. At T3, 47 monosensitized and 46 polysensitized children were effectively treated, with no significant between-group difference in efficacy (P > .05). The TNSS, SMS, VAS scores, and RQLQ score were significantly lower at T1, T2, T3, and T5 than at T0 in both groups (P < .05). The differences in the TNSS, SMS, VAS score, and RQLQ score between the 2 groups were nonsignificant at T0, T1, T2, and T3 (P > .05), but significant at T5 (P < .05). No serious AEs were reported. CONCLUSION: Monosensitized and polysensitized children exhibited similar beneficial efficacy and safety after 3 years of dust mite SCIT. Monosensitized children derived more benefits 2 years after discontinuation.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Yuan X, Xie S, Zhang H, et al. Long-Term Efficacy and Safety of Subcutaneous Immunotherapy in Monosensitized and Polysensitized Children With Allergic Rhinitis. Otolaryngol Head Neck Surg. 2023. PMID: 38104318. doi:10.1002/ohn.614

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。